Canaccord initiated coverage of Progyny with a Buy rating and $46 price target. Progyny has established itself as “the market leader in specialized fertility” and continues to ride a “wave of growth,” the analyst tells investors. Progyny acheived record new client wins in 2022 and is describing the 2023 selling season pipeline as “favorable,” the analyst added.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PGNY:
- Progyny Celebrates More Than 30,000 Amazonians Supported on Their Family Building Journeys
- Progyny price target raised to $52 from $48 at Truist
- Maven Clinic partners with Amazon to offer fertility, family-building support
- Progyny Unveils Nationwide Access to Menopause Care
- Progyny announces expansion of health network to include menopause care